Cover Image
市場調查報告書

Cellmid Limited 產品平台分析

Cellmid Limited - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 256002
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
Cellmid Limited 產品平台分析 Cellmid Limited - Product Pipeline Review - 2015
出版日期: 2015年10月30日 內容資訊: 英文 30 Pages
簡介

Cellmid Limited 是總公司設立於澳洲的生物科技企業。正在進行癌症,發炎,自體免疫疾病,心缺血疾病診斷藥及治療藥的開發,其開發計劃有腫瘤抗體的AB102,發炎抗體的CAB101,心缺血治療藥的CMK103等。

本報告提供Cellmid Limited 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,加上最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Cellmid Limited 基本資料

  • Cellmid Limited 概要
  • 主要資訊
  • 企業資料

Cellmid Limited :R&D概要

  • 主要的治療範圍

Cellmid Limited :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Cellmid Limited :開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Cellmid Limited :藥物簡介

  • CAB-101
  • CAB-102
  • CMK-103
  • hu-91
  • Monoclonal Antibody to Inhibit Midkine for Cancer and Inflammatory Disorders
  • siRNAs to Inhibit Midkine for Cardiovascular Diseases

Cellmid Limited :開發平台分析

  • 各分子類型

Cellmid Limited :最新的開發平台情形

Cellmid Limited :開發暫停中的計劃

Cellmid Limited :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07714CDB

Summary

Global Markets Direct's, 'Cellmid Limited - Product Pipeline Review - 2015', provides an overview of the Cellmid Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cellmid Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Cellmid Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Cellmid Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Cellmid Limited's pipeline products

Reasons to buy

  • Evaluate Cellmid Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Cellmid Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Cellmid Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Cellmid Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cellmid Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Cellmid Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Cellmid Limited Snapshot
    • Cellmid Limited Overview
    • Key Information
    • Key Facts
  • Cellmid Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Cellmid Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Cellmid Limited - Pipeline Products Glance
    • Cellmid Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Cellmid Limited - Drug Profiles
    • Antisense RNAi Oligonucleotides to Inhibit Midkine for Cardiovascular Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CAB-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CAB-102
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CMK-103
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hu-91
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Midkine for Cancer and Inflammatory Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Midkine for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cellmid Limited - Pipeline Analysis
    • Cellmid Limited - Pipeline Products by Target
    • Cellmid Limited - Pipeline Products by Molecule Type
    • Cellmid Limited - Pipeline Products by Mechanism of Action
  • Cellmid Limited - Recent Pipeline Updates
  • Cellmid Limited - Dormant Projects
  • Cellmid Limited - Dormant Projects
  • Cellmid Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Cellmid Limited, Key Information
  • Cellmid Limited, Key Facts
  • Cellmid Limited - Pipeline by Indication, 2015
  • Cellmid Limited - Pipeline by Stage of Development, 2015
  • Cellmid Limited - Monotherapy Products in Pipeline, 2015
  • Cellmid Limited - Preclinical, 2015
  • Cellmid Limited - Discovery, 2015
  • Cellmid Limited - Pipeline by Target, 2015
  • Cellmid Limited - Pipeline by Molecule Type, 2015
  • Cellmid Limited - Pipeline Products by Mechanism of Action, 2015
  • Cellmid Limited - Recent Pipeline Updates, 2015
  • Cellmid Limited - Dormant Developmental Projects,2015
  • Cellmid Limited, Subsidiaries

List of Figures

  • Cellmid Limited - Pipeline by Top 10 Indication, 2015
  • Cellmid Limited - Pipeline by Stage of Development, 2015
  • Cellmid Limited - Monotherapy Products in Pipeline, 2015
  • Cellmid Limited - Pipeline by Top 10 Target, 2015
  • Cellmid Limited - Pipeline by Top 10 Molecule Type, 2015
  • Cellmid Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top